Alaunos reports positive preclinical data for ALN1003; weight loss up to 12.9% in DIO mice

Alaunos Therapeutics, Inc.

ALN1003 showed dose-dependent body weight loss: -12.9% peak (Day 34) and -10.3% after 48 days vs DIO control (p<0.0001).
Liver weight reduced 43% (p<0.0001); liver enzymes ALT, AST, ALP significantly decreased in Study 1.
Highest-dose group lowered glucose to 197 mg/dL (vs 320 control) and total cholesterol to 162 mg/dL (vs 209).
Cash and equivalents ~$1.9M as of Sept 30, 2025; runway into Q2 2026; additional financing being pursued.
ALN1003 is an oral non-hormonal small molecule; company planning IND-enabling studies and next-gen compounds.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.